RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges

RadNet posts record Q3 revenue and EBITDA, but net income remains modest.

What the company is saying

RadNet, Inc. reports record third-quarter revenue of $638.3 million and Adjusted EBITDA of $105.0 million, highlighting a 22.1% and 23.8% year-over-year increase, respectively. The company attributes these results to capacity expansion, new center openings, a shift toward advanced imaging, tuck-in acquisitions, improved commercial reimbursement, and a 32.6% revenue jump in its Digital Health segment. Dr. Howard Berger, President and CEO, emphasizes the expansion of the advanced imaging business mix to 30.6% and points to strong procedural volume growth across MRI, CT, and PET/CT. The company raises its 2026 guidance for the Imaging Center segment, citing outperformance in each of the first three quarters, and maintains Digital Health segment guidance. RadNet also highlights the pending ONRAD acquisition, describing strong inbound interest from partners and customers but provides no financial specifics. The tone is confident, focusing on operational momentum, liquidity strength, and anticipated benefits from strategic acquisitions.

What the data suggests

The disclosed figures show robust top-line and operational growth, with Q3 2026 revenue up $115.4 million year-over-year and Adjusted EBITDA up $20.2 million. Adjusted EBITDA margin expanded by 23 basis points, and advanced imaging volumes rose 19.9% in aggregate and 8.9% on a same-center basis. MRI, CT, and PET/CT volumes increased 18.3%, 22.0%, and 30.4%, respectively, while overall imaging exam volume climbed 10.8%. Digital Health revenue grew 32.6% to $32.9 million, but its Adjusted EBITDA declined by $0.4 million. Net income for Q3 was $4.2 million, down from $5.4 million a year ago, and diluted EPS fell to $0.05 from $0.07. Adjusted for one-time items, Q3 Adjusted Earnings were $23.8 million ($0.30 per share), up from $18.8 million ($0.24 per share). For the first nine months, revenue reached $1,836.6 million and Adjusted EBITDA $268.0 million, but the company posted a net loss of $21.8 million. Cash at quarter-end was $750.6 million, with a net debt to Adjusted EBITDA ratio of 1.66x. The company raised 2026 guidance for Imaging Center revenue ($2,385–$2,435 million), Adjusted EBITDA ($350–$363 million), and free cash flow ($120–$130 million), but Digital Health guidance was unchanged. The data supports claims of operational momentum but reveals that sustained GAAP profitability remains elusive.

Analysis

The announcement is generally positive and supported by strong realised revenue and Adjusted EBITDA growth, with detailed operational metrics and segment-level data. However, the company’s unadjusted net income declined year-over-year for the quarter, and it reported a net loss for the first nine months of 2026, indicating that profitability remains a challenge despite top-line growth. The raised guidance for 2026 is forward-looking and not yet realised, and the pending ONRAD acquisition is referenced without quantification or timeline, making its impact uncertain. Capital expenditures are significant ($170–$180 million), and the benefits from these investments are not immediate but projected over the coming quarters. The language around 'strong inbound interest' and 'opportunities that could result' from the ONRAD acquisition is promotional and not substantiated by data. Overall, while operational momentum is clear, the gap between revenue growth and bottom-line profitability, as well as the forward-looking nature of some claims, tempers the signal.

Risk flags

• ●Despite record revenue and EBITDA, RadNet's unadjusted net income declined year-over-year for the quarter and the company posted a net loss for the first nine months of 2026, indicating that profitability is not yet consistently achieved. This raises concerns about the sustainability of bottom-line improvements if revenue growth slows or costs rise.
• ●The company is increasing capital expenditures to $170–$180 million and raising free cash flow guidance, but significant ongoing investment is required to maintain growth. If operational leverage does not improve or if acquisitions underperform, returns on this capital could disappoint.
• ●The pending ONRAD acquisition is referenced as a strategic growth driver, but no financial terms, timeline, or quantified synergies are disclosed. This lack of detail introduces uncertainty around the magnitude and timing of any benefits, as well as integration risks.
• ●Digital Health segment Adjusted EBITDA declined in both the quarter and year-to-date periods despite strong revenue growth, suggesting margin pressure or high investment requirements in this segment. If this trend continues, it could weigh on consolidated profitability.
• ●A number of one-time items, including $7.5 million in gains from joint venture contributions and $5.4 million in equipment disposal losses, materially affect reported earnings. Heavy reliance on adjusted figures may obscure underlying profitability trends and complicate comparisons across periods.

Bottom line

RadNet delivered strong Q3 revenue and Adjusted EBITDA growth, driven by advanced imaging expansion and Digital Health momentum, but net income remains modest and the company is still reporting a year-to-date net loss. The raised 2026 guidance for the Imaging Center segment is grounded in realised operational outperformance, yet sustained GAAP profitability is not yet established. The pending ONRAD acquisition is positioned as a strategic catalyst, but the absence of financial details or a closing timeline leaves its impact unquantified and subject to execution risk. High capital expenditures and reliance on adjusted earnings figures underscore the need for careful scrutiny of underlying cash generation and margin trends. Investors should focus on whether RadNet can translate top-line and volume growth into consistent bottom-line profitability and monitor the actual integration and financial contribution of ONRAD. The most important takeaway is that while operational momentum is clear, the path to sustained net income remains the key challenge.

Announcement summary

(NASDAQ: RDNT) RadNet, Inc. reported financial results for its third quarter of 2026, highlighting record quarterly Revenue and Adjusted EBITDA. Total Company Revenue for Q3 2026 was $638.3 million, representing a 22.1% increase over the prior year, and Adjusted EBITDA was $105.0 million, up 23.8%. The Adjusted EBITDA margin expanded by 23 basis points. These results were attributed to initiatives such as capacity creation at existing centers, new center openings, a shift toward advanced imaging, tuck-in acquisitions, improved commercial payor reimbursement, expansion of health system joint ventures, and 32.6% revenue growth in the Digital Health segment. Aggregate advanced imaging procedural volumes increased 19.9% year-over-year, and same-center advanced imaging procedural volumes increased 8.9%. The advanced imaging business mix rose from 28.2% in Q3 2025 to 30.6% in Q3 2026, an increase of 232 basis points. MRI volume increased 18.3%, CT volume increased 22.0%, and PET/CT volume increased 30.4% compared to Q3 2025. Overall imaging exam volume increased 10.8% year-over-year, and same-center overall volume increased 3.2%. Digital Health Revenue for Q3 2026 was $32.9 million, up $8.1 million or 32.6%, while Adjusted EBITDA for the segment was $3.0 million, down $0.4 million or -11.8%. Unadjusted Total Company Net Income for Q3 2026 was $4.2 million, compared to $5.4 million in Q3 2025. Fully diluted Net Income Per Share was $0.05, compared to $0.07 in Q3 2025, with 79.2 million diluted shares outstanding in Q3 2026. Noteworthy items impacting Q3 included $1.2 million in severance expense, $7.5 million gain on contribution of imaging centers into joint ventures, $0.6 million expense for leases on de novo facilities under construction, $5.4 million loss on equipment disposal, $7.3 million intangibles amortization for Digital Health, $5.6 million non-capitalized R&D expenses for DeepHealth Cloud OS and AI, $2.8 million in legal settlements, $2.7 million acquisition transaction costs, $8.3 million non-cash change in contingent consideration, and $2.1 million lease abandonment charges. Adjusted for these items, Total Company Adjusted Earnings for Q3 2026 was $23.8 million and diluted Adjusted Earnings Per Share was $0.30, compared to $18.8 million and $0.24, respectively, in Q3 2025. For the first nine months of 2026, Total Company Revenue was $1,836.6 million, up $344.1 million or 23.1%, and Adjusted EBITDA was $268.0 million, up $55.4 million or 26.1%. Digital Health Revenue for the nine months was $94.5 million, up $29.7 million or 45.8%, and Adjusted EBITDA was $6.8 million, down $3.7 million or -35.4%. Unadjusted Total Company Net Loss for the nine months was $21.8 million, compared to $18.1 million in the prior year. Fully diluted Net Loss Per Share for the nine months was $(0.28), compared to $(0.24) in 2025, with 77.6 million diluted shares outstanding. At the end of Q3 2026, RadNet had $750.6 million in cash and a Net Debt to Adjusted EBITDA leverage ratio of 1.66x. The company raised its 2026 Imaging Center guidance ranges: Total Net Revenue to $2,385 - $2,435 million, Adjusted EBITDA to $350 - $363 million, Capital Expenditures to $170 - $180 million, Cash Interest Expense to $48 - $53 million, and Free Cash Flow to $120 - $130 million. Digital Health segment guidance was maintained for Total Net Revenue at $135 - $145 million, Adjusted EBITDA before non-capitalized R&D at $11 - $13 million, Non-Capitalized R&D at $17 - $19 million, Capital Expenditures at $10 - $13 million, Free Cash Flow before non-capitalized R&D at $(1) - $3 million, and Free Cash Flow after non-capitalized R&D at $(17) - $(19) million. The company referenced the pending acquisition of ONRAD and noted strong inbound interest from joint venture partners and customers. Dr. Howard Berger is President and Chief Executive Officer, and Mark Stolper is Executive Vice President and Chief Financial Officer. A conference call to discuss results was scheduled for November 9, 2026.

Disagree with this article?